Chris H.
About Chris H.
Chris H. is the Sr. Director, Market Access Lead Sub-Region Europe at BeiGene with extensive experience in market access and pricing strategies across Europe.
Current Position at BeiGene
Chris H. currently holds the position of Sr. Director, Market Access Lead Sub-Region Europe at BeiGene. In this role, Chris leads the Market Access function across 22 countries, including Switzerland, the Netherlands, the Nordics, Central & Eastern Europe, Greece, Cyprus, and Malta. Chris has been instrumental in defining pricing and reimbursement strategies, ensuring market access for key oncology treatments across the region.
Professional Background
Chris H. has extensive experience in market access and pricing within the pharmaceutical industry. Prior to his current role at BeiGene, Chris served as the Director, Head of Market Access for Central & Eastern Europe, Greece, Cyprus, and Malta. He also held the position of Country Manager for Poland, providing interim leadership for market access strategies. Before joining BeiGene, Chris worked at Abbott as Sr. Director, Global Head of Market Access & Pricing and Director, Global Market Access Strategy and Excellence, with responsibilities spanning strategic insights and planning.
Consulting Experience
Chris H. has a robust background in consulting, having worked at ZS as Manager and Consultant in Strategy Insights and Planning. He also served as a Management Consultant in Pricing and Market Access at PriceSpective LLC, and in Clinical Research Services and Healthcare Compliance at Huron. These roles involved developing market access strategies and providing key insights for pharmaceutical companies, enhancing their market positioning and compliance measures.
Educational Background
Chris H. has a diverse educational background, holding an MBA in Marketing/Decision Support from Indiana University - Kelley School of Business. Additionally, he earned a Master of Arts in Slavic Languages, Literatures, and Linguistics (Polish), and a Bachelor of Music in Clarinet Performance from Indiana University Bloomington. Furthermore, he obtained a diploma in Polish Language and Literature from Jagiellonian University, reflecting a strong foundational knowledge in both business and the arts.
Key Achievements
Chris H. has achieved significant milestones in his career, notably securing reimbursement for zanubrutinib in chronic lymphocytic leukemia (CLL) in Poland within a record 411 days after Marketing Authorization. He also achieved reimbursement for zanubrutinib in CLL in the Netherlands, Czech Republic, and Bulgaria, and for zanubrutinib in Waldenström's macroglobulinemia (WM) in Bulgaria. These accomplishments demonstrate his expertise in market access and his ability to navigate complex regulatory environments to achieve favorable outcomes for patients and stakeholders.